Trials / Completed
CompletedNCT00002001
The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Glaxo Wellcome · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the virologic effect of combined administration of zidovudine and ddI or ddC. To evaluate the immunologic effects of zidovudine and ddI or ddC. To evaluate combined administration of zidovudine and ddI or ddC for clinical efficacy. To evaluate the safety and the tolerance of the coadministration of zidovudine and ddI or ddC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zidovudine | |
| DRUG | Zalcitabine | |
| DRUG | Didanosine |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
5 sites across 3 countries: United States, Australia, Puerto Rico
Source: ClinicalTrials.gov record NCT00002001. Inclusion in this directory is not an endorsement.